pulmonary fibrosis/misselijkheid

De link wordt op het klembord opgeslagen

Kies het sorteertype

Bladzijde 1 van 83 resultaten

Real-Life Experience with Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina. A Retrospective Multicenter Study.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Pirfenidone was the first antifibrotic drug approved in Argentina for idiopathic pulmonary fibrosis (IPF). Outcomes in real life may differ from the results of clinical trials. The primary endpoint was to study the tolerance of pirfenidone in real life. Secondary endpoints were to analyze

Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Nintedanib (Ofev(®)) inhibits receptor tyrosine kinases implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This article reviews the efficacy and tolerability of oral nintedanib in the treatment of IPF, as well as summarizing its pharmacological properties. In the randomized,

Oral lesions and pulmonary fibrosis after ingesting grapes.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

A young rural man referred to us with profound icterus and dyspnea after he had eaten three grapes almost 10 days earlier. He had referred to a local hospital 30 min after ingestion with nausea, vomiting and abdominal pain and was conservatively managed. He then became icteric and began to

Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a poor prognosis. Recently, pirfenidone was reported to slow the rate of decline in vital capacity and improve progression-free survival in IPF. The purpose of this study was to clarify the factors that

South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Purpose: Pirfenidone and nintedanib are two novel antifibrotic agents licensed for the treatment IPF. Prior to being approved for use in England for patients with FVC >50% and <80%, these were made available for all IPF patients under the Mild Patient Program (MPP) and Patient In Need

Pirfenidone in idiopathic pulmonary fibrosis.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis for which, until recently, there were no effective treatments. Pirfenidone (5-methyl-1-phenylpyridin-2[1H]-one) is a novel antifibrotic agent that has been demonstrated to slow disease progression in patients with

Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Introduction. Angiosarcoma is a rare cancer of the inner lining of blood vessels and can arise anywhere in the body, most commonly presenting as cutaneous disease in elderly patient, involving head and neck (H&N), especially the scalp. Pegylated liposomal doxorubicin (PLD) is one of the available

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although the precise cause of the disease is still unknown, recent studies have shown that the pathogenesis of pulmonary fibrosis involves multiple mechanisms, with abnormal behavior of alveolar epithelial cells

Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a fatal condition with limited treatment options. However, in a previous small study, co-trimoxazole was found to be beneficial. METHODS In a double-blind multicentre study, 181 patients with fibrotic idiopathic interstitial pneumonia (89% diagnosed

Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. In this meta-analysis, we analyzed the adverse events (AEs) of PFD for the treatment of pulmonary fibrosis. METHODS We performed a

The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

In this study we aimed to investigate the effectiveness and safety profile of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in a real-life setting.Clinical records of patients diagnosed with mild-to-moderate IPF and receiving

Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Pirfenidone (Esbriet®) is an orally administered, synthetic, pyridone compound that is approved for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU, and for the treatment of IPF in the USA. This article summarizes pharmacological, efficacy and tolerability

Factor analysis identifies three separate symptom clusters in idiopathic pulmonary fibrosis

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Idiopathic pulmonary fibrosis (IPF) is a severe and progressive lung disease with a poor prognosis. Patients with IPF suffer from a high symptom burden, which impairs their health-related quality of life (HRQoL). Lack of research on IPF symptoms and their clustering, however, makes symptom-centred

Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis

Alleen geregistreerde gebruikers kunnen artikelen vertalen

Background: In the phase III trial of nintedanib, only 10.8% of participants were aged ≥75 years. Here, we aimed to evaluate the tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis (IPF).

Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer.

Alleen geregistreerde gebruikers kunnen artikelen vertalen

BACKGROUND Chemotherapy with oxaliplatin and 5-fluorouracil (5-FU)/folinic acid is the standard first-line therapy of metastatic colorectal carcinoma and has shown activity in several other malignancies. This regimen is mostly well tolerated. Known side effects include myelosuppression,

Vorige
1
2
3
4
5
6
De volgende

Word lid van onze
facebookpagina

Herbal & Natural Medicine

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap

Werkt in 55 talen
Kruidengeneesmiddelen gesteund door de wetenschap
Kruidenherkenning door beeld
Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
Zoek medicinale kruiden op hun effecten
Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten

Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek